Valencia / Mannheim / Columbus / Indianapolis / Santa Cruz / /
Company
TIGAR / Human Biology Laboratory / AMP / UV No Ab / E No Ab / RB Ab / Las Vegas NV / RB IPP anti-RB Ab / Cancer Research UK British Journal / Altogen Biosciences / Cancer Research UK / RB IPP anti-E2F1 Ab / /
Country
United States / India / /
Currency
pence / / /
Event
FDA Phase / Product Issues / /
Facility
E2F1 complex / Nehru University / D1 complex / National Center / NPL4 complex / CDK complex / Ohio State University Medical Centre / Chhatrapati Shahuji Maharaj Medical University / /
IndustryTerm
cellcycle machinery / cell culture media / microtubular network / energy / chromatin solution / cellular energy / cell-cycle machinery / energy deprivation / /
MedicalCondition
retinoblastoma / endometrial carcinoma / aggressive cancer / human tumours / dissociation / rapidly dividing cancer / Cancer / tumour / cancer cells / mice bearing tumours / tumours / /
MedicalTreatment
antibiotics / chemotherapy / Radiotherapy / /
NaturalFeature
TIGAR falls / /
Organization
National Institute of Health / School of Biotechnology / Ohio State University Medical Centre / Department of Biochemistry / Nehru University / New Delhi / Chhatrapati Shahuji Maharaj Medical University / Lucknow / National Center for Cell Sciences / /
TIGAR induces p53-mediated cell-cycle arrest by regulation of RB–E2F1 complex